Characteristics of unpublished registered studies: DNA‐based vaccine (18 studies)
Registration number	Registration date	Status	Design	Interventions	Estimated sample size	Phase
ChiCTR2000038152	11 September 2020	Completed	Parallel	INO‐4800 + electroporation	45	Phase 1
NCT04527081	26 August 2020	Completed	Parallel	AG0302‐COVID19	30	Phase 1/Phase 2
CTRI/2020/07/026352	4 July 2020	Not recruiting	Adaptive	nCov vaccine	1048	Phase 1/Phase 2
CTRI/2021/03/032051	16 March 2021	Not recruiting	Parallel	ZyCov‐D	150	Phase 1/Phase 2
NCT04655625	7 July 2020	Not recruiting	Parallel	AG0302‐COVID19	500	Phase 2/Phase 3
NCT04742842	8 February 2021	Not recruiting	Sequential assignment	COVIGEN	150	Phase 1
NCT04993586	6 August 2021	Not recruiting	Parallel	AG0302‐COVID19	80	Phase 1/Phase 2
JPRN‐jRCT2051210052	16 July 2021	Not recruiting	Parallel	AG0302‐COVID19	400	Phase 1/Phase 2
NCT05067946	5 October 2021	Not recruiting	Parallel	Gx‐19n	14,000	Phase 2/Phase 3
NCT05085639	20 October 2021	Not recruiting	Parallel	GLS‐5130	30	Phase 1
NCT05102643	1 November 2021	Not recruiting	Sequential assignment	SARS‐CoV‐2 DNA vaccine + electroporation	30	Phase 1
CTRI/2021/01/030416	12 January 2021	Ongoing	Parallel	ZyCov‐D	28,216	Phase 3
NCT04445389	24 June 2020	Ongoing	Parallel	GX‐19	210	Phase 1/Phase 2
NCT04447781	25 June 2020	Ongoing	Sequential assignment	INO‐4800 + electroporation	160	Phase 1/Phase 2
NCT04591184	19 October 2020	Ongoing	Parallel	Covigenix VAX‐001	72	Phase 1/Phase 2
NCT04673149	17 December 2020	Ongoing	Parallel	GLS‐5310	345	Phase 1/Phase 2
NCT05047445	17 September 2021	Ongoing	Parallel	Covidity	40	Phase 1
NCT04715997	20 January 2021	Ongoing	Sequential assignment	GX‐19N	170	Phase 1/Phase 2